Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) Sees Large Growth in Short Interest

Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) saw a significant increase in short interest in April. As of April 30th, there was short interest totaling 523,399 shares, an increase of 363.6% from the April 15th total of 112,896 shares. Based on an average daily volume of 4,873,175 shares, the days-to-cover ratio is presently 0.1 days. Currently, 6.0% of the shares of the company are sold short.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on the company. Wall Street Zen raised Cumberland Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Saturday, March 14th. Weiss Ratings reissued a “sell (d-)” rating on shares of Cumberland Pharmaceuticals in a research note on Friday, March 27th. One research analyst has rated the stock with a Sell rating, According to MarketBeat, Cumberland Pharmaceuticals currently has a consensus rating of “Sell”.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the company. Perceptive Advisors LLC bought a new position in Cumberland Pharmaceuticals during the fourth quarter valued at about $1,358,000. Dimensional Fund Advisors LP boosted its stake in Cumberland Pharmaceuticals by 11.1% during the third quarter. Dimensional Fund Advisors LP now owns 280,869 shares of the specialty pharmaceutical company’s stock valued at $876,000 after buying an additional 27,980 shares in the last quarter. Bridgeway Capital Management LLC boosted its stake in Cumberland Pharmaceuticals by 2.3% during the second quarter. Bridgeway Capital Management LLC now owns 188,355 shares of the specialty pharmaceutical company’s stock valued at $631,000 after buying an additional 4,200 shares in the last quarter. Geode Capital Management LLC boosted its stake in Cumberland Pharmaceuticals by 5.6% during the fourth quarter. Geode Capital Management LLC now owns 107,274 shares of the specialty pharmaceutical company’s stock valued at $427,000 after buying an additional 5,653 shares in the last quarter. Finally, Marshall Wace LLP bought a new position in Cumberland Pharmaceuticals during the fourth quarter valued at about $192,000. Institutional investors own 15.51% of the company’s stock.

Cumberland Pharmaceuticals Trading Down 0.9%

Shares of CPIX stock opened at $4.53 on Wednesday. The stock has a 50-day simple moving average of $3.49 and a 200 day simple moving average of $3.46. Cumberland Pharmaceuticals has a fifty-two week low of $1.85 and a fifty-two week high of $6.26. The stock has a market capitalization of $67.86 million, a P/E ratio of -9.24 and a beta of -0.06. The company has a quick ratio of 0.84, a current ratio of 0.95 and a debt-to-equity ratio of 0.25.

Cumberland Pharmaceuticals (NASDAQ:CPIX) last announced its earnings results on Tuesday, May 5th. The specialty pharmaceutical company reported ($0.13) earnings per share for the quarter, meeting the consensus estimate of ($0.13). Cumberland Pharmaceuticals had a negative return on equity of 12.01% and a negative net margin of 17.60%.The business had revenue of $9.13 million during the quarter, compared to analysts’ expectations of $8.50 million.

Cumberland Pharmaceuticals Company Profile

Cumberland Pharmaceuticals Inc (NASDAQ:CPIX) is a specialty pharmaceutical company based in Nashville, Tennessee, focused on the development, manufacture and commercialization of hospital and acute care products. Founded in 1993, the company has built a portfolio of branded therapeutics designed to address critical care needs in emergency medicine, critical care units and other hospital settings. Cumberland’s strategy emphasizes in-licensing and acquiring products that have established safety and efficacy profiles but limited market reach, then leveraging its sales network to expand their commercial footprint.

The company’s flagship products include Acetadote (N-acetylcysteine injection), the only FDA-approved antidote for acetaminophen overdose administered intravenously; Vasostrict (vasopressin injection), used to raise blood pressure in adults with vasodilatory shock; Cerebrex (diclofenac sodium injection), an anti-inflammatory agent for managing acute pain and fever; and Dynastat (parecoxib sodium), a COX-2 inhibitor for postoperative pain relief.